Ole H Larsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/102328/publications.pdf Version: 2024-02-01



OLE HLADSEN

#	Article	lF	CITATIONS
1	Diagnostic Performance and Therapeutic Consequence of Thromboelastometry Activated by Kaolin <i>versus</i> Â a Panel of Specific Reagents. Anesthesiology, 2011, 115, 294-302.	2.5	116
2	The Role of Platelets in Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2016, 42, 242-251.	2.7	56
3	Evaluation of platelet function in thrombocytopenia. Platelets, 2018, 29, 270-276.	2.3	39
4	Thrombocytopenia model with minimal manipulation of blood cells allowing whole blood assessment of platelet function. Platelets, 2016, 27, 295-300.	2.3	31
5	Whole blood laboratory model of thrombocytopenia for use in evaluation of hemostatic interventions. Annals of Hematology, 2007, 86, 217-221.	1.8	28
6	Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential. Cells, 2020, 9, 1362.	4.1	20
7	Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue. British Journal of Haematology, 2009, 144, 99-106.	2.5	14
8	Streptokinase Treatment Reverses Biofilm-Associated Antibiotic Resistance in Staphylococcus aureus. Microorganisms, 2016, 4, 36.	3.6	14
9	Combination of recombinant factor <scp>VII</scp> a and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. British Journal of Haematology, 2013, 160, 228-236.	2.5	12
10	Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram: A Nordic study. Haemophilia, 2019, 25, 334-342.	2.1	12
11	Ageâ€stratified reference intervals unlock the clinical potential of circulating cellâ€free <scp>DNA</scp> as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer. International Journal of Cancer, 2021, 148, 1665-1675.	5.1	9
12	SERPINC1 variants causing hereditary antithrombin deficiency in a Danish population. Thrombosis Research, 2019, 175, 68-75.	1.7	6
13	Continuous exploration of parameters derived from multiple electrode platelet aggregometry is warranted. Thrombosis Research, 2018, 164, 45-47.	1.7	5
14	Protein C deficiency; PROC gene variants in a Danish population. Thrombosis Research, 2020, 185, 153-159.	1.7	5
15	Local Vancomycin Concentrations after Intra-articular Injection into the Knee Joint: An Experimental Porcine Study. Journal of Knee Surgery, 2021, 34, 936-940.	1.6	5
16	Deleterious misâ€splicing of <i>STK11</i> caused by a novel singleâ€nucleotide substitution in the 3′ polypyrimidine tract of intron five. Molecular Genetics & Genomic Medicine, 2020, 8, e1381.	1.2	3
17	Systemic versus free antibiotic delivery in preventing acute exogenous implant related infection in a rat model. Journal of Orthopaedic Research, 2021, , .	2.3	1
18	Genetic Variants in the Protein S (PROS1) Gene and Protein S Deficiency in a Danish Population. TH Open, 2021, 05, e479-e488.	1.4	1

#	Article	IF	CITATIONS
19	What the Standard APTT Didn't Tell You - Dynamic Plasma Clotting Parameters Reveal Hypercoagulation Blood, 2005, 106, 2634-2634.	1.4	0
20	Combination of Recombinant Factor VIIa and Fibrinogen Corrects Clot Formation in Primary Immune Thrombocytopenia At Very Low Platelet Counts. Blood, 2011, 118, 4667-4667.	1.4	0